Orphanet: An Open Label, randomized, phase III trial to evaluate the efficacy and safety of Aztreonam AZLI versus TOBI® TNS, Tobramycin Nebuliser Solution in an intermittent aerosolized antibiotic regimen in patients with Cystic fibrosis, followed by an open label, single arm extension BE.
x

Search for a clinical trial

* (*) mandatory field

An Open-Label, randomized, phase III trial to evaluate the efficacy and safety of Aztreonam (AZLI) versus TOBI (TNS, Tobramycin Nebuliser Solution) in an intermittent aerosolized antibiotic regimen in patients with Cystic fibrosis, followed by an open-label, single arm extension - BE.

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Gilead sciences international limited
  • Website
    • Phase : III
  • Principal investigator of clinical trial

  • Pr Patrick LEBECQUE
  • Centre de rfrence de la mucoviscidose
  • Cliniques universitaires Saint-Luc - UCLouvain
  • Avenue Hippocrate, 10
  • 1200 BRUSSELS
  • BELGIUM
  • More information
  • Phone  : +32 (0)2 764 19 39
  • Fax  : -
  • Website
  • Contact secretary  :
  • Principal investigator of clinical trial

  • Pr Teresinha LAL
  • Louvain centre for Toxicology and Applied Pharmacology
  • Institut de recherche exprimentale et clinique
  • Universit Catholique de Louvain (UCL)
  • avenue E. Mounier, 53-B1.52.12
  • 1200 BRUSSELS
  • BELGIUM
  • More information
  • Phone  : +32 (0)2 764 53 30
  • Fax  : +32 (0)2 764 53 58
  • Website
  • Contact secretary  :
Last update: March 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.